Review

Outcome measures for chronic inflammatory demyelinating polyneuropathy in research: relevance and applicability to clinical practice

*Author for correspondence:

School of Life & Health Sciences & Aston Medical School, Aston University, Birmingham, UK

Regional Neuromuscular Service, University Hospitals Birmingham, Birmingham, UK

Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Aix Marseille University, CNRS (UMR 7339), Centre de Résonance Magnétique Biologique et Médicale, Faculté de Médecine, 27 bd. J. Moulin, 13005 Marseille, France

Search for more papers by this author

Published Online:3 Oct 2019https://doi.org/10.2217/nmt-2019-0009

View article

Abstract

Outcome measures are recommended in the management of chronic inflammatory demyelinating polyneuropathy (CIDP). Various scales have been proposed in recent years, some now commonly utilized in daily clinical practice. The available evidence base relies itself on randomized controlled trial data obtained over the past 30 years, with several studies using different primary and secondary outcomes. We here review the different outcome measures used in CIDP research in relation to those currently recommended for clinical management. We consider the evidence base for CIDP treatment from the primary and secondary outcomes used in these studies and attempt to assess how this may relate to current clinical practice of routine evaluation of treatment effects and long-term monitoring.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Breiner A, Barnett C, Bril V. Incat disability score: a critical analysis of its measurement properties. Muscle Nerve 50(2), 164–169 (2014). •• Appraises the inflammatory neuropathy cause and treatment scale.
MedlineGoogle Scholar
2. Anon. Aids to the investigation of peripheral nerve injuries. J. Neurol. Psychiatry 6(1–2), 81 (1943).
Google Scholar
3. Vanhoutte EK, Faber CG, van Nes SI et al. Modifying the medical research council grading system through Rasch analyses. Brain 135(5), 1639–1649 (2012). •• Article on study of limitations of the classical Medical Research Council scale.
MedlineGoogle Scholar
4. Dyck PJ, Turner DW, Davies JL et al. Electronic case-report forms of symptoms and impairments of peripheral neuropathy. Can. J. Neurol. Sci. 29(3), 258–266 (2002).
MedlineGoogle Scholar
5. Rankin J. Cerebral vascular accidents in patients over the age of 60: I. General considerations. Scott. Med. J. 2(4), 127–136 (1957).
Medline CASGoogle Scholar
6. Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 2(8093), 750–753 (1978).
Medline CASGoogle Scholar
7. Sharrack B, Hughes RA. The Guy’s neurological disability scale (GNDS): a new disability measure for multiple sclerosis. Mult. Scler. J. 5(4), 223–233 (1999).
Medline CASGoogle Scholar
8. Merkies ISJ, Schmitz PIM, van der Meché FGA, Samijn JPA, van Doorn PA, Inflammatory Neuropathy Cause and Treatment (INCAT) group. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J. Neurol. Neurosurg. Psychiatry 72(5), 596–601 (2002).
Medline CASGoogle Scholar
9. Merkies IS, Schmitz PI, van der Meché FG, van Doorn PA. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. inflammatory neuropathy cause and treatment (INCAT) group. Neurology 54(4), 943–949 (2000).
Medline CASGoogle Scholar
10. Graham RC, Hughes RAC. A modified peripheral neuropathy scale: the overall neuropathy limitations scale. J. Neurol. Neurosurg. Psychiatry 77(8), 973–976 (2006).
Medline CASGoogle Scholar
11. van Nes SI, Vanhoutte EK, van Doorn PA et al. Rasch-built overall disability scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 76(4), 337–345 (2011). • Describes derivation of the inflammatory rash-built overall disability scale for chronic inflammatory demyelinating polyneuropathy (CIDP).
Medline CASGoogle Scholar
12. Rajabally YA, Narasimhan M. Jamar hand-held grip dynamometry in chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci. 325(1–2), 36–38 (2013).
MedlineGoogle Scholar
13. Draak THP, Pruppers MHJ, van Nes SI et al. Grip strength comparison in immune-mediated neuropathies: Vigorimeter vs. Jamar. J. Peripher. Nerv. Syst. 20(3), 269–276 (2015). • Article on a study of grip strength relevance in CIDP.
MedlineGoogle Scholar
14. Harbo T, Markvardsen LK, Hellfritzsch MB, Severinsen K, Nielsen JF, Andersen H. Neuromuscular electrical stimulation in early rehabilitation of Guillain-Barre Syndrome: a pilot study. Muscle Nerve 59(4), 481–484 (2018).
Google Scholar
15. Dyck PJ, Litchy WJ, Kratz KM et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 36(6), 838–845 (1994).
Medline CASGoogle Scholar
16. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 119(Pt 4), 1067–1077 (1996).
MedlineGoogle Scholar
17. Mendell JR, Barohn RJ, Freimer ML et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56(4), 445–449 (2001).
Medline CASGoogle Scholar
18. Vermeulen M, van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J. Neurol. Neurosurg. Psychiatry 56(1), 36–39 (1993).
Medline CASGoogle Scholar
19. Thompson N, Choudhary P, Hughes RA, Quinlivan RM. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol. 243(3), 280–285 (1996).
Medline CASGoogle Scholar
20. Hughes R, Bensa S, Willison H et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann. Neurol. 50(2), 195–201 (2001).
Medline CASGoogle Scholar
21. Hughes RA, Donofrio P, Bril V et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 7(2), 136–144 (2008).
Medline CASGoogle Scholar
22. RMC Trial Group. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol. 8(2), 158–164 (2009).
MedlineGoogle Scholar
23. Kuitwaard K, van den Berg LH, Vermeulen M et al. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol. Neurosurg. Psychiatry 81(12), 1374–1379 (2010).
Medline CASGoogle Scholar
24. Nobile-Orazio E, Cocito D, Jann S et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial. Lancet Neurol. 11(6), 493–502 (2012).
Medline CASGoogle Scholar
25. Camdessanche J-P, Ferraud K, Lagrange E et al. Multicentre, randomised, open-label trial to compare efficacy and tolerance of prednisone and IVIG in patients with CIDP on a one year follow up (P7.092). Neurology 82(Suppl. 10), Abstract P7.092 (2014).
Google Scholar
26. Markvardsen LH, Harbo T. Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs. J. Neurol. Sci. 378, 19–25 (2017).
Medline CASGoogle Scholar
27. Kuwabara S, Mori M, Misawa S et al. Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week Phase III trial. J. Neurol. Neurosurg. Psychiatry 88(10), 832–838 (2017).
MedlineGoogle Scholar
28. van Schaik IN, Bril V, van Geloven N et al. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet Neurol. 17(1), 35–46 (2018).
MedlineGoogle Scholar
29. Dyck PJ, O’Brien PC, Oviatt KF et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann. Neurol. 11(2), 136–141 (1982).
Medline CASGoogle Scholar
30. van Schaik IN, Eftimov F, van Doorn PA et al. Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol. 9(3), 245–253 (2010).
Medline CASGoogle Scholar
31. Dyck PJ, Daube J, O’Brien P et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N. Engl. J. Med. 314(8), 461–465 (1986).
Medline CASGoogle Scholar
32. Hahn AF, Bolton CF, Pillay N et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 119(Pt 4), 1055–1066 (1996).
MedlineGoogle Scholar
33. Rai SK, Yazdany J, Fortin PR, Aviña-Zubieta JA. Approaches for estimating minimal clinically important differences in systemic lupus erythematosus. Arthritis Res. Ther. 17(1), 143 (2015).
MedlineGoogle Scholar
34. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control. Clin. Trials 10(4), 407–15 (1989).
Medline CASGoogle Scholar
35. Engel L, Beaton DE, Touma Z. Minimal clinically important difference. Rheum. Dis. Clin. North Am. 44(2), 177–188 (2018).
MedlineGoogle Scholar
36. Eftimov F, Vermeulen M, van Doorn PA, Brusse E, van Schaik IN. Long-term remission of CIDP after pulsed dexamethasone or short-term prednisolone treatment. Neurology 78(14), 1079–1084 (2012).
Medline CASGoogle Scholar
37. Merkies ISJ, van Nes SI, Hanna K, Hughes RAC, Deng C. Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J. Neurol. Neurosurg. Psychiatry 81(11), 1194–1199 (2010). •• Article describing the reanalysis of a major CIDP randomized controlled trial with relevance to MCID.
Medline CASGoogle Scholar
38. Spina E, Topa A, Iodice R et al. Six-minute walk test is reliable and sensitive in detecting response to therapy in CIDP. J. Neurol. 266(4), 860–865 (2019).
MedlineGoogle Scholar
39. Fukumori N, Yamamoto Y, Takegami M et al. Association between hand-grip strength and depressive symptoms: locomotive syndrome and health outcomes in Aizu cohort study (LOHAS). Age Ageing 44(4), 592–598 (2015).
MedlineGoogle Scholar
40. Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. In: Cochrane Database of Systematic Reviews. van Schaik IN. (Ed.). John Wiley & Sons, Ltd, Chichester, UK, CD001797 (2009).
Google Scholar
41. Wimperis J, Lunn M, Jones A et al. Clinical guidelines for immunoglobulin use. Second edition update (2011). https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216671/dh_131107.pdf
Google Scholar
42. Gwathmey KG, Sadjadi R, Horton WB et al. Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy. Neurology 90(23), e2034–e2041 (2018).
MedlineGoogle Scholar
43. Bjelica B, Peric S, Gwathmey K et al. Chronic acquired polyneuropathy patient reported index (CAPPRI) in chronic inflammatory demyelinating polyradiculoneuropathy. J. Peripher. Nerv. Syst. 24(3), 247–252 (2019).
MedlineGoogle Scholar

Vol. 9, No. 5

Metrics

Downloaded 151 times

History

Received 3 May 2019

Accepted 8 August 2019

Published online 3 October 2019

Published in print October 2019

Information

Keywords

Financial & competing interests disclosure

YA Rajabally has received consultancy and speaker fees from LFB Biomedicaments, CSL Behring and Grifols and has received research support from LFB Biomedicaments and CSL Behring. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download